Floatz logo

Inno-206

Adrenocortical Carcinoma

National Cancer Institute (NCI)Phase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Adrenocortical Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Vanderbilt-Ingram Cancer Center
Phase 2BB
Nivolumab
Dana-Farber Cancer Institute
Phase 2B
Pembrolizumab
Corcept Therapeutics
Phase 2B
Cyclophosphamide
Anusha Kalbasi
Phase 2B
Eloxatin
National Cancer Institute (NCI)
Phase 2B

View all 43 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →